Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.

Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group..

Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078.

2.

Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.

Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, Montalbán X, Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group..

Neurology. 2011 Aug 30;77(9):835-43. doi: 10.1212/WNL.0b013e31822c90d7. Erratum in: Neurology. 2011 Sep 27;77(13):1317.

PMID:
21849647
3.

The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis.

Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, Suchet L, Hyde R, Balla I, Frohman EM, Kieseier BC; GAP Study Group..

Eur J Neurol. 2011 Jan;18(1):69-77. doi: 10.1111/j.1468-1331.2010.03110.x.

PMID:
20561039
4.

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators..

J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012.

PMID:
20236661
5.

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.

Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group..

Lancet Neurol. 2009 Nov;8(11):987-97. doi: 10.1016/S1474-4422(09)70237-6.

PMID:
19748319
6.

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group., O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G.

Lancet Neurol. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Erratum in: Lancet Neurol. 2011 Feb;10(2):115. Lancet Neurol. 2009 Nov;8(11):981. Lancet Neurol. 2012 Jan;11(1):27. Cree, B [added]; Harung, H-P [corrected to Hartung, H-P].

PMID:
19729344
7.

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

Multiple Sclerosis Therapy Consensus Group (MSTCG)., Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R.

J Neurol. 2008 Oct;255(10):1449-63. doi: 10.1007/s00415-008-0061-1.

PMID:
19005625
8.

Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.

Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sørensen PS, Maas-Enriquez M, Sommerauer B, Hanna K; PRIVIG Study Group.; UBC MS/MRI Research Group..

Neurology. 2008 Jul 22;71(4):265-71. doi: 10.1212/01.wnl.0000318281.98220.6f.

PMID:
18645164
9.

Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.

Minagara A, Murray TJ; PROOF Study Investigators..

Curr Med Res Opin. 2008 Apr;24(4):1049-55. doi: 10.1185/030079908X280545 .

PMID:
18315940
10.

Brain activation patterns elicited by the 'Faces Symbol Test' -- a pilot fMRI study.

Grabner R, Popotnig F, Ropele S, Neuper C, Gorani F, Petrovic K, Ebner F, Strasser-Fuchs S, Fazekas F, Enzinger C.

Mult Scler. 2008 Apr;14(3):354-63. doi: 10.1177/1352458507084030.

PMID:
18208887
11.

Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b.

Polman C, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Selmaj K, Uitdehaag BM, Dahms S, Bauer L, Pohl C, Sandbrink R; BENEFIT investigators..

J Neurol. 2008 Apr;255(4):480-7.

PMID:
18004635
12.

Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox?

Strasser-Fuchs S, Enzinger C, Ropele S, Wallner M, Fazekas F.

Mult Scler. 2008 Mar;14(2):205-11.

PMID:
17986507
13.

Intravenous immunoglobulin in MS: promise or failure?

Fazekas F, Strasser-Fuchs S, Hommes OR.

J Neurol Sci. 2007 Aug 15;259(1-2):61-6. Review.

PMID:
17449063
14.

The impact of our genes: consequences of the apolipoprotein E polymorphism in Alzheimer disease and multiple sclerosis.

Fazekas F, Enzinger C, Ropele S, Schmidt H, Schmidt R, Strasser-Fuchs S.

J Neurol Sci. 2006 Jun 15;245(1-2):35-9. Review.

PMID:
16631796
15.

Relapsing acute transverse myelitis: a specific entity.

Seifert T, Enzinger C, Ropele S, Storch MK, Strasser-Fuchs S, Fazekas F.

Eur J Neurol. 2005 Sep;12(9):681-4. Review.

PMID:
16128868
16.

Discrimination of white matter lesions and multiple sclerosis plaques by short echo quantitative 1H-magnetic resonance spectroscopy.

Kapeller P, Ropele S, Enzinger C, Lahousen T, Strasser-Fuchs S, Schmidt R, Fazekas F.

J Neurol. 2005 Oct;252(10):1229-34.

PMID:
15895306
17.

Tumefactive demyelinating lesions: conventional and advanced magnetic resonance imaging.

Enzinger C, Strasser-Fuchs S, Ropele S, Kapeller P, Kleinert R, Fazekas F.

Mult Scler. 2005 Apr;11(2):135-9.

PMID:
15794384
18.

Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

Rieckmann P, Toyka KV, Bassetti C, Beer K, Beer S, Buettner U, Chofflon M, Götschi-Fuchs M, Hess K, Kappos L, Kesselring J, Goebels N, Ludin HP, Mattle H, Schluep M, Vaney C, Baumhackl U, Berger T, Deisenhammer F, Fazekas F, Freimüller M, Kollegger H, Kristoferitsch W, Lassmann H, Markut H, Strasser-Fuchs S, Vass K, Altenkirch H, Bamborschke S, Baum K, Benecke R, Brück W, Dommasch D, Elias WG, Gass A, Gehlen W, Haas J, Haferkamp G, Hanefeld F, Hartung HP, Heesen C, Heidenreich F, Heitmann R, Hemmer B, Hense T, Hohlfeld R, Janzen RW, Japp G, Jung S, Jügelt E, Koehler J, Kölmel W, König N, Lowitzsch K, Manegold U, Melms A, Mertin J, Oschmann P, Petereit HF, Pette M, Pöhlau D, Pohl D, Poser S, Sailer M, Schmidt S, Schock G, Schulz M, Schwarz S, Seidel D, Sommer N, Stangel M, Stark E, Steinbrecher A, Tumani H, Voltz R, Weber F, Weinrich W, Weissert R, Wiendl H, Wiethölter H, Wildemann U, Zettl UK, Zipp F, Zschenderlein R, Izquierdo G, Kirjazovas A, Packauskas L, Miller D, Koncan Vracko B, Millers A, Orologas A, Panellus M, Sindic CJ, Bratic M, Svraka A, Vella NR, Stelmasiak Z, Selmaj K, Bartosik-Psujik H, Mitosek-Szewczyk K, Belniak E, Mochecka A, Bayas A, Chan A, Flachenecker P, Gold R, Kallmann B, Leussink V, Mäurer M, Ruprecht K, Stoll G, Weilbach FX; Multiple Sclerosis Therapy Consensus Group..

J Neurol. 2004 Nov;251(11):1329-39. Review.

PMID:
15592728
19.

[Health care costs of multiple sclerosis in Austria. Cross-sectional study including consideration of quality of life].

Ganzinger U, Badelt C, Vass K, Strasser-Fuchs S, Fazekas F, Berger T, Dahlke F.

Nervenarzt. 2004 Oct;75(10):1000-6. German.

PMID:
15150646
20.

Accelerated evolution of brain atrophy and "black holes" in MS patients with APOE-epsilon 4.

Enzinger C, Ropele S, Smith S, Strasser-Fuchs S, Poltrum B, Schmidt H, Matthews PM, Fazekas F.

Ann Neurol. 2004 Apr;55(4):563-9.

PMID:
15048896
Items per page

Supplemental Content

Loading ...
Support Center